Kura Oncology (NASDAQ:KURA) Stock Passes Above 50 Day Moving Average – Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $10.28 and traded as high as $10.57. Kura Oncology shares last traded at $10.39, with a volume of 1,137,954 shares trading hands.

Analyst Ratings Changes

KURA has been the topic of a number of research reports. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Lake Street Capital started coverage on shares of Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price for the company. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $25.46.

Kura Oncology Trading Down 0.6%

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The business’s 50-day moving average is $10.28 and its two-hundred day moving average is $9.28. The firm has a market cap of $922.32 million, a P/E ratio of -3.10 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. The company had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. As a group, analysts predict that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after purchasing an additional 1,587,959 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the last quarter. Renaissance Technologies LLC increased its position in Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after acquiring an additional 965,256 shares during the period. AQR Capital Management LLC increased its stake in Kura Oncology by 36.6% during the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after acquiring an additional 820,020 shares during the period. Finally, Qube Research & Technologies Ltd raised its stake in Kura Oncology by 63.0% in the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.